This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Conference 2024 - Rare Disease Summit
March 19-21, 2024
Pre-Conference Workshops on March 18, 2024Philadelphia Marriott Downtown | Philadelphia, PA

Johanna Rossell
Senior Vice President, General Manager, Rare Disease at Sumitomo Pharma


As Senior Vice President, General Manager, Rare Disease, at Sumitomo Pharma America, Johanna oversees commercial activities for RETHYMIC® and leads the company’s efforts to make this groundbreaking regenerative medicine available to more patients. She also provides leadership for Sumitomo Pharma America’s growth strategies in rare disease, including expansions into new geographies.

With broad and deep background across consumer goods and healthcare categories in the U.S. and several geographies around the world, Johanna brings a unique and nuanced perspective to long-term strategic planning. She has led multifunctional teams delivering strong business results for companies such as Procter & Gamble, Novartis, Merck, Mallinckrodt and Biogen. She has had extensive success leading new products to the U.S. market and creating integrated pre- and post-launch commercial plans, both in the U.S. and globally, including a Regenerative Medicine Advanced Therapy (RMAT)-designated tissue-based product and several therapies for rare diseases.

Johanna received a Bachelor of Science in Computer Engineering and an MBA from Simon Bolivar University in Caracas, Venezuela.

Agenda Sessions

  • Promoting a Pre-Competitive Rare Disease Knowledge Ecosystem